Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Cheson, B. D., Horning, S., Coiffier, B., Shipp, M., Fisher, R. I., Connors, J. M., Lister, T., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,210 · see citing works

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Rummel, M., Niederle, N., Maschmeyer, G., Banat, G.-A., von Grünhagen, U., Losem, C. J., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,512 · see citing works

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Salles, G., Seymour, J. F., Offner, F. C., López‐Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62175-7 · Cited by 1,075 · see citing works

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

Smith, T. J., Bohlke, K., Lyman, G. H., Carson, K. R., Crawford, J., Cross, S. J., Goldberg, J. M., Khatcheressian, J. L., Leighl, N. B., Perkins, C. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3488 · Cited by 907 · see citing works

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814 · see citing works

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

Marcus, R. E., Davies, A. J., Ando, K., Klapper, W., Opat, S., Owen, C., Phillips, E. H., Sangha, R. S., Schlag, R., Seymour, J. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614598 · Cited by 802 · see citing works

Testing for Qualitative Interactions between Treatment Effects and Patient Subsets

Gail, M., & Simon, R. (1985) · Biometrics · doi:10.2307/2530862 · Cited by 651 · see citing works

Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.

Brice, P., Bastion, Y., Lepage, É., Brousse, N., Haïoun, C., Moreau, P., Straetmans, N., Tilly, H., Tabah-Fisch, I. M., & Solal‐Céligny, P. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1110 · Cited by 646 · see citing works

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Flinn, I. W., van der Jagt, R., Kahl, B. S., Wood, P., Hawkins, T. E., Macdonald, D. A., Hertzberg, M., Kwan, Y., Simpson, D., Craig, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-531327 · Cited by 644 · see citing works

Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate <scp>T</scp> cells by inducing degradation of <scp>T</scp> cell repressors <scp>I</scp> karos and <scp>A</scp> iolos via modulation of the <scp>E</scp> 3 ubiquitin ligase complex <scp>CRL</scp> 4 <scp> ^CRBN </scp>

Gandhi, A. K., Kang, J., Havens, C. G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M. F., Thakurta, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12708 · Cited by 619 · see citing works

Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis

Schulz, H., Bohlius, J., Trelle, S., Skoetz, N., Reiser, M. F., Kober, T., Schwarzer, G., Herold, M., Dreyling, M. H., Hallek, M. J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk152 · Cited by 362 · see citing works

Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource

Link, B. K., Maurer, M. J., Nowakowski, G. S., Ansell, S. M., Macon, W. R., Syrbu, S., Slager, S. L., Thompson, C. A., Inwards, D. J., Johnston, P. B., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.3990 · Cited by 334 · see citing works

Pathogenesis of follicular lymphoma

Kridel, R., Sehn, L. H., & Gascoyne, R. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63186 · Cited by 310 · see citing works

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

Fowler, N. H., Davis, R. E., Rawal, S., Nastoupil, L. J., Hagemeister, F. B., McLaughlin, P. J., Kwak, L. W., Romaguera, J. E., Fanale, M. A., Fayad, L., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70455-3 · Cited by 264 · see citing works

Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituximab in vivo

Reddy, N. M., Hernandez‐Ilizaliturri, F. J., Deeb, G., Roth, M. S., Vaughn, M. S., Knight, J., Wallace, P. K., & Czuczman, M. S. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06841.x · Cited by 260 · see citing works

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

Ramsay, A. G., Clear, A. J., Kelly, G. P., Fatah, R., Matthews, J., MacDougall, F., Lister, T. A., Lee, A. M., Calaminici, M., & Gribben, J. G. (2009) · Blood · doi:10.1182/blood-2009-04-217687 · Cited by 240 · see citing works

Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications

Crawford, J., Caserta, C., & Roila, F. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq195 · Cited by 232 · see citing works

Histologic progression in non-Hodgkin's lymphoma

Hubbard, S., Chabner, B. A., DeVita, V. J., Simon, R. M., Berard, C. W., Jones, R., Garvin, A., Canellos, G., Osborne, C. K., & Young, R. (1982) · Blood · doi:10.1182/blood.v59.2.258.258 · Cited by 227 · see citing works

Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4

Bjorklund, C. C., Lu, L., Kang, J., Hagner, P. R., Havens, C. G., Amatangelo, M., Wang, M., Ren, Y., Couto, S., Breider, M., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.66 · Cited by 221 · see citing works

Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model

Hernandez‐Ilizaliturri, F. J., Reddy, N. M., Holkova, B., Ottman, E., & Czuczman, M. S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0577 · Cited by 174 · see citing works

Transformed follicular non-Hodgkin lymphoma

Casulo, C., Burack, R., & Friedberg, J. W. (2014) · Blood · doi:10.1182/blood-2014-04-516815 · Cited by 165 · see citing works

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

Zhang, L. N., Qian, Z., Cai, Z., Sun, L., Wang, H., Bartlett, J. B., Yi, Q., & Wang, M. L. (2009) · American Journal of Hematology · doi:10.1002/ajh.21468 · Cited by 146 · see citing works

Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds

Lagrue, K., Carisey, A. F., Morgan, D. J., Chopra, R., & Davis, D. M. (2015) · Blood · doi:10.1182/blood-2015-01-625004 · Cited by 132 · see citing works

Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials

Shi, Q., Flowers, C. R., Hiddemann, W., Marcus, R. E., Herold, M. J., Hagenbeek, A., Kimby, E. K., Höchster, H. S., Vitolo, U., Peterson, B. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.8651 · Cited by 120 · see citing works

Ikaros regulates neutrophil differentiation

Dumortier, A., Kirstetter, P., Kastner, P., & Chan, S. H. (2003) · Blood · doi:10.1182/blood-2002-05-1336 · Cited by 95 · see citing works

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance)

Martin, P., Jung, S., Pitcher, B. N., Bartlett, N. L., Blum, K. A., Shea, T., Hsi, E. D., Ruan, J., Smith, S. E., Leonard, J. P., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx496 · Cited by 83 · see citing works

Clinical Features, Prognosis and Treatment of Follicular Lymphoma

Salles, G. (2007) · Hematology · doi:10.1182/asheducation-2007.1.216 · Cited by 76 · see citing works

Long term follow-up of the PRIMA study : half of patients receiving rituximab maintenance remain progression free at 10 years

Salles, G., Seymour, J. F., Feugier, P., Offner, F. C., López‐Guillermo, A., Belada, D., Xerri, L., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2017) · Ghent University Academic Bibliography (Ghent University) · Cited by 47 · see citing works

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Kimby, E. K., Rondeau, S., Vanazzi, A., Østenstad, B., Mey, U., Rauch, D., Wahlin, B. E., Hitz, F., Hernberg, M., Johansson, A., et al. (2016) · Blood · doi:10.1182/blood.v128.22.1099.1099 · Cited by 9 · see citing works

Combination of Lenalidomide and Rituximab (R2) Targets Immune Dysfunction in FL By Activating T and NK Cells Ex Vivo and Is Differentiated from Chemotherapy

Chiu, H., Hagner, P. R., Trisal, P., Waldman, M. F., Cavanaugh, C., & Gandhi, A. K. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.1531.1531 · Cited by 3 · see citing works

Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

Morschhauser, F., Tilly, H., Chaidos, A., McKay, P., Phillips, T., Assouline, S. E., Batlevi, C. L., Campbell, P., Ribrag, V., Damaj, G. L., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30441-1 · Cited by 612 · see citing works

AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma

Leonard, J. P., Trneny, M., Izutsu, K., Fowler, N. H., Hong, X., Zhu, J., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00010 · Cited by 434 · see citing works

Follicular lymphoma

Carbone, A., Roulland, S., Gloghini, A., Younes, A., von Keudell, G., López‐Guillermo, A., & Fitzgibbon, J. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0132-x · Cited by 287 · see citing works

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Dreyling, M. H., Ghielmini, M. E. G., Rule, S. A., Salles, G., Ladetto, M., Tonino, S. H., Herfarth, K. K., Seymour, J. F., & Jerkeman, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.008 · Cited by 270 · see citing works

Follicular lymphoma: 2020 update on diagnosis and management

Freedman, A. S., & Jacobsen, E. D. (2019) · American Journal of Hematology · doi:10.1002/ajh.25696 · Cited by 268 · see citing works

Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups

Batlevi, C. L., Sha, F., Alperovich, A., Ni, A., Smith, K., Ying, Z., Soumerai, J. D., Caron, P. C., Falchi, L., Hamilton, A., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00340-z · Cited by 209 · see citing works

Follicular lymphoma: 2023 update on diagnosis and management

Jacobsen, E. D. (2022) · American Journal of Hematology · doi:10.1002/ajh.26737 · Cited by 139 · see citing works

Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide

Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137 · see citing works

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

Morschhauser, F., Nastoupil, L. J., Feugier, P., de Colella, J. S., Tilly, H., Palomba, M. L., Bachy, E., Fruchart, C., Libby, E. N., Casasnovas, O., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00843 · Cited by 121 · see citing works

Molecular mechanisms of thalidomide and its derivatives

Ito, T., & Handa, H. (2020) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.96.016 · Cited by 121 · see citing works

B-cell non-Hodgkin lymphomas

Silkenstedt, E., Salles, G., Campo, E., & Dreyling, M. H. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02705-8 · Cited by 123 · see citing works

Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study

Luminari, S., Manni, M., Galimberti, S., Versari, A., Tucci, A., Boccomini, C., Farina, L., Olivieri, J., Marcheselli, L., Guerra, L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01234 · Cited by 96 · see citing works

International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline 18 F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation

Boellaard, R., Buvat, I., Nioche, C., Ceriani, L., Cottereau, A., Guerra, L., Hicks, R. J., Kanoun, S., Kobe, C., Loft, A., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.267789 · Cited by 74 · see citing works

Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study

Casulo, C., Larson, M. C., Lunde, J. J., Habermann, T. M., Lossos, I. S., Wang, Y., Nastoupil, L. J., Strouse, C. S., Chihara, D., Martin, P., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00033-3 · Cited by 68 · see citing works

Anti-CD20 treatment for B-cell malignancies: current status and future directions

Klein, C., Jamois, C., & Nielsen, T. G. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1822318 · Cited by 64 · see citing works

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)

Zhu, J., Ma, J., & Union for China Lymphoma Investigators of the Chinese Society of Clinical Oncology (2021) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2021.03.01 · Cited by 65 · see citing works

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Zucca, E., Rondeau, S., Vanazzi, A., Østenstad, B., Mey, U., Rauch, D., Wahlin, B. E., Hitz, F., Hernberg, M., Johansson, A., et al. (2019) · Blood · doi:10.1182/blood-2018-10-879643 · Cited by 63 · see citing works

Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs

Matasar, M. J., Luminari, S., Barr, P. M., Barta, S. K., Danilov, A. V., Hill, B. T., Phillips, T. J., Jerkeman, M., Magagnoli, M., Nastoupil, L. J., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0138 · Cited by 61 · see citing works

Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma

Westin, J. R., Davis, R. E., Feng, L., Hagemeister, F. B., Steiner, R. E., Lee, H. J., Fayad, L., Nastoupil, L. J., Ahmed, S., Rodriguez, M. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00597 · Cited by 60 · see citing works

Diagnosis and management of follicular lymphoma: A comprehensive review

Dada, R. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13271 · Cited by 59 · see citing works

Follicular lymphoma: The long and winding road leading to your cure?

Gordon, M. J., Smith, M. R., & Nastoupil, L. J. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100992 · Cited by 54 · see citing works

Emerging therapies in mantle cell lymphoma

Hanel, W. G., & Epperla, N. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00914-1 · Cited by 50 · see citing works

Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination

Lew, T. E., & Seymour, J. F. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01295-3 · Cited by 50 · see citing works

SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial

Song, Y., Liu, Y., Li, Z., Li, L., Su, H., Jin, Z., Zuo, X., Wu, J., Zhou, H., Li, K., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00134-x · Cited by 50 · see citing works

Follicular Lymphoma in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms—Updated Classification and New Biological Data

Kurz, K. S., Kalmbach, S., Ott, M., Staiger, A. M., Ott, G., & Horn, H. (2023) · Cancers · doi:10.3390/cancers15030785 · Cited by 50 · see citing works

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma

Bartlett, N. L., Hahn, U., Kim, W. S., Fleury, I., Laribi, K., Bergua, J., Bouabdallah, K. K., Forward, N. A., Bijou, F. D., Macdonald, D. A., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02242 · Cited by 49 · see citing works

Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma

Chiu, H., Trisal, P., Bjorklund, C. C., Carrancio, S., Toraño, E. G., Guarinós, C., Papazoglou, D., Hagner, P. R., Beldi‐Ferchiou, A., Tarte, K., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15797 · Cited by 48 · see citing works

Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis

Saleem, K., Franz, J. K., Klem, M. L., Yabes, J. G., Boyiadzis, M. M., Jones, J. R., Shaikh, N., & Lontos, K. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00289-7 · Cited by 48 · see citing works

Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life

Sortais, C., Lok, A., Tessoulin, B., Gastinne, T., Mahé, B., Dubruille, V., Blin, N., Touzeau, C., Moreau, A., Bossard, C., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04025-2 · Cited by 47 · see citing works

Immunotherapy of lymphomas

Ansell, S. M., & Lin, Y. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129206 · Cited by 47 · see citing works

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma

Strati, P., Ahmed, M. A., Fowler, N. H., Nastoupil, L. J., Samaniego, F., Fayad, L., Hagemeister, F. B., Romaguera, J. E., Rodriguez, M. A., Wang, M. L., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.230649 · Cited by 44 · see citing works

Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives

Dalle, I. A., Duléry, R., Moukalled, N. M., Ricard, L., Stocker, N., Cheikh, J. E., Mohty, M., & Bazarbachi, A. A. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-00989-w · Cited by 42 · see citing works

Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm

Laurent, C., Dietrich, S., & Tarte, K. (2023) · Blood · doi:10.1182/blood.2023021000 · Cited by 41 · see citing works

How we treat mature B-cell neoplasms (indolent B-cell lymphomas)

Lumish, M. A., Falchi, L., Imber, B. S., Scordo, M., von Keudell, G., & Joffe, E. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01018-6 · Cited by 41 · see citing works

High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B

Laurent, C., Adélaı̈de, J., Guillé, A., Tesson, B. M., Gat, E., Evrard, S., Escudié, F., Syrykh, C., Canioni, D., Fabiani, B., et al. (2021) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001726 · Cited by 40 · see citing works

Immunomodulatory Drugs for the Treatment of B Cell Malignancies

Ioannou, N., Jain, K., & Ramsay, A. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168572 · Cited by 40 · see citing works

Development of new agents for peripheral T-cell lymphoma

Ito, Y., Makita, S., & Tobinai, K. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1572746 · Cited by 37 · see citing works

Lenalidomide in follicular lymphoma

Flowers, C. R., Leonard, J. P., & Fowler, N. H. (2020) · Blood · doi:10.1182/blood.2019001751 · Cited by 38 · see citing works

Pathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation

Kumar, E. A., Pickard, L., & Okosun, J. (2021) · British Journal of Haematology · doi:10.1111/bjh.17383 · Cited by 38 · see citing works

How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation

Perini, G. F., Fischer, T. R. D. C., Gaiolla, R. D., Rocha, T. B., Bellesso, M., Teixeira, L. L. C., Delamain, M. T., Scheliga, A. A. D. S., Ribeiro, G., Neto, J. V. P., et al. (2020) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2020.04.002 · Cited by 36 · see citing works

Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial

Cottereau, A., Rebaud, L., Trotman, J., Feugier, P., Nastoupil, L. J., Bachy, E., Flinn, I. W., Haïoun, C., Ysebaert, L., Bartlett, N. L., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.121 · Cited by 36 · see citing works

Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study

Bachy, E., Houot, R., Feugier, P., Bouabdallah, K. K., Bouabdallah, R., Nicolas‐Virelizier, E., Maerevoet, M., Fruchart, C., Snauwaert, S., Gouill, S. L., et al. (2021) · Blood · doi:10.1182/blood.2021013526 · Cited by 36 · see citing works

The investigation and management of follicular lymphoma

McNamara, C., Montoto, S., Eyre, T. A., Ardeshna, K. M., Burton, C., Illidge, T., Linton, K., Rule, S. A., Townsend, W. M., Wong, W. L., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16872 · Cited by 35 · see citing works

Reporting harms more transparently in trials of cancer drugs

Gyawali, B., Shimokata, T., Honda, K., & Ando, Y. (2018) · BMJ · doi:10.1136/bmj.k4383 · Cited by 34 · see citing works

CD19-directed CAR T-cell therapy in B-cell NHL

Kersten, M. J., Spanjaart, A. M., & Thiéblemont, C. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000668 · Cited by 33 · see citing works

Lymphomas and Their Microenvironment: A Multifaceted Relationship

Menter, T., & Tzankov, A. (2019) · Pathobiology · doi:10.1159/000502912 · Cited by 33 · see citing works

Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study

Michot, J., Bouabdallah, R., Vitolo, U., Doorduijn, J. K., Salles, G., Chiappella, A., Zinzani, P. L., Bijou, F. D., Kersten, M. J., Sarmiento, R., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30208-8 · Cited by 32 · see citing works

Lenalidomide and Rituximab Regimen Combined With Intravitreal Methotrexate Followed by Lenalidomide Maintenance for Primary Vitreoretinal Lymphoma: A Prospective Phase II Study

Zhang, Y., Zhang, X., Zou, D., Yin, J., Zhang, L., Wang, X., Jia, C., Wang, W. J., Zhao, D., Zhou, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.701507 · Cited by 32 · see citing works

Time for an individualized approach to first-line management of follicular lymphoma

Cartron, G., & Trotman, J. (2022) · Haematologica · doi:10.3324/haematol.2021.278766 · Cited by 32 · see citing works

Update on follicular lymphoma

Friedberg, J. W. (2023) · Hematological Oncology · doi:10.1002/hon.3138 · Cited by 31 · see citing works

ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma

Abramson, J. S., Ghosh, N., & Smith, S. M. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279043 · Cited by 30 · see citing works

Follicular lymphoma dynamics

Milpied, P., Gandhi, A. K., Cartron, G., Pasqualucci, L., Tarte, K., Nadel, B., & Roulland, S. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.05.002 · Cited by 28 · see citing works

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma

Lu, T., Zhang, J., Xu-Monette, Z. Y., & Young, K. H. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00432-z · Cited by 31 · see citing works

IMiDs New and Old

Yamshon, S., & Ruan, J. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00536-6 · Cited by 30 · see citing works

Prospects in the management of patients with follicular lymphoma beyond first-line therapy

Qualls, D. A., & Salles, G. (2022) · Haematologica · doi:10.3324/haematol.2021.278717 · Cited by 29 · see citing works

The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma

Fowler, N. H., Nastoupil, L. J., de Vos, S., Knapp, M. H., Flinn, I. W., Chen, R., Advani, R. H., Bhatia, S., Martin, P., Mena, R. R., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16424 · Cited by 28 · see citing works

Follicular Lymphoma: a Focus on Current and Emerging Therapies

Cahill, K. E. (2022) · ONCOLOGY · doi:10.46883/2022.25920946 · Cited by 28 · see citing works

Clinical advances in epigenetic therapies for lymphoma

Rosenthal, A. C., Munoz, J. L., & Villasboas, J. C. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01452-6 · Cited by 28 · see citing works

Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303

Russler‐Germain, D. A., Krysiak, K., Ramirez, C. A., Mosior, M., Watkins, M. P., Gomez, F., Skidmore, Z. L., Trani, L., Gao, F., Geyer, S. M., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010779 · Cited by 28 · see citing works

Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies

Hanel, W. G., & Epperla, N. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01113-2 · Cited by 27 · see citing works

First‐line R‐CVP versus R‐CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4

Walewski, J. A., Paszkiewicz‐Kozik, E., Michalski, W., Rymkiewicz, G., Szpila, T., Butrym, A. K., Giza, A., Zaucha, J. M., Kalinka‐Warzocha, E., Wieczorkiewicz, A., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16264 · Cited by 26 · see citing works

The tumor microenvironment of lymphomas: Insights into the potential role and modes of actions of checkpoint inhibitors

Menter, T., Tzankov, A., & Dirnhofer, S. (2020) · Hematological Oncology · doi:10.1002/hon.2821 · Cited by 24 · see citing works

Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas

Revailler, W., Cottereau, A., Rossi, C., Noyelle, R., Trouillard, T., Morschhauser, F., Casasnovas, O., Thiéblemont, C., Gouill, S. L., André, M. P. E., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12020417 · Cited by 24 · see citing works

Controversies in the Treatment of Follicular Lymphoma

Hübel, K., Ghielmini, M. E. G., Ladetto, M., & Gopal, A. K. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000317 · Cited by 24 · see citing works

Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed/refractory follicular lymphoma: final analysis of a Phase Ib/II trial

Morschhauser, F., Ghosh, N., Lossos, I. S., Palomba, M. L., Mehta, A., Casasnovas, O., Stevens, D. A., Katakam, S. B., Knapp, A., Nielsen, T. G., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00539-8 · Cited by 23 · see citing works

Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccine

Lapenta, C., Donati, S., Spadaro, F., Lattanzi, L., Urbani, F., Macchia, I., Sestili, P., Spada, M., Cox, M. C., Belardelli, F., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02411-y · Cited by 22 · see citing works

The fifth edition of the WHO classification of mature B‐cell neoplasms: open questions for research

Coupland, S. E., Du, M., Ferry, J. A., de Jong, D., Khoury, J. D., Leoncini, L., Naresh, K. N., Ott, G., Siebert, R., Xerri, L., et al. (2024) · The Journal of Pathology · doi:10.1002/path.6246 · Cited by 22 · see citing works

The 5th edition of the World Health Organization Classification of mature lymphoid and stromal tumors – an overview and update

Attygalle, A. D., Chan, J. K. C., Coupland, S. E., Du, M., Ferry, J. A., de Jong, D., Gratzinger, D. A., Lim, M. S., Naresh, K. N., Nicolae, A., et al. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2297939 · Cited by 24 · see citing works

A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

Evens, A. M., Hong, F., Habermann, T. M., Advani, R. H., Gascoyne, R. D., Witzig, T. E., Quon, A. S. W., Ranheim, E. A., Ansell, S. M., Cheema, P. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1345 · Cited by 22 · see citing works

From Molecular Precision to Clinical Practice: A Comprehensive Review of Bispecific and Trispecific Antibodies in Hematologic Malignancies

Amoozgar, B., Bangolo, A., Habibi, M., Cho, C., & Goy, A. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115319 · Cited by 21 · see citing works

Follicular lymphoma and macrophages: impact of approved and novel therapies

Gouni, S., Marques-Piubelli, M. L., & Strati, P. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005722 · Cited by 21 · see citing works

Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma

Saleh, K., Cheminant, M., Chiron, D., Burroni, B., Ribrag, V., & Sarkozy, C. (2022) · Cancers · doi:10.3390/cancers14133229 · Cited by 22 · see citing works

Therapy-related myeloid neoplasms in lymphoma survivors: Reducing risks

Al-Juhaishi, T. M. S., Khurana, A., & Shafer, D. A. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.02.008 · Cited by 21 · see citing works

Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy

Menter, T., Tzankov, A., Zucca, E., Kimby, E. K., Hultdin, M., Sundström, C., Beiske, K., Cogliatti, S., Banz, Y., Cathomas, G., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16414 · Cited by 21 · see citing works

Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study

Delfau‐Larue, M., Boulland, M., Beldi‐Ferchiou, A., Feugier, P., Maisonneuve, H., Casasnovas, O., Lemonnier, F., Pica, G. M., Houot, R., Ysebaert, L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001955 · Cited by 21 · see citing works

Is it time for PET-guided therapy in follicular lymphoma?

Trotman, J., & Pettitt, A. R. (2021) · Blood · doi:10.1182/blood.2020008243 · Cited by 21 · see citing works

Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms

Guo, H., Yang, J., Wang, H., Liu, X., Liu, Y., & Zhou, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1017990 · Cited by 21 · see citing works

B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)

Infante, M. S., Salmanton‐García, J., Fernández‐Cruz, A., Marchesi, F., Jakšić, O., Weinbergerová, B., Besson, C., Duarte, R. F., Itri, F., Valković, T., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.992137 · Cited by 19 · see citing works

Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials

Wang, Y., Zhou, S., Qi, X., Yang, F., Maurer, M. J., Habermann, T. M., Witzig, T. E., Wang, M. L., & Nowakowski, G. S. (2022) · Blood Cancer Journal · doi:10.1038/s41408-021-00598-x · Cited by 18 · see citing works

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma

Mohty, R., & Kharfan‐Dabaja, M. A. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221142133 · Cited by 18 · see citing works

Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review

Patel, K. K., Ivanov, A., Jocelyn, T., Hantel, A., Garcia, J. S., & Abel, G. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.14425 · Cited by 19 · see citing works

Follicular lymphoma comprises germinal center–like and memory-like molecular subtypes with prognostic significance

Laurent, C., Trisal, P., Tesson, B. M., Seth, S., Beyou, A., Roulland, S., Lesne, B., Acker, N. V., Cerapio, J., Chartier, L., et al. (2024) · Blood · doi:10.1182/blood.2024024496 · Cited by 18 · see citing works

Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma

Cheson, B. D., Morschhauser, F., & Martin, P. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.03.009 · Cited by 18 · see citing works

Exercise training (ET) in adult and elderly patients receiving anti-lymphoma treatments is feasible and may improve the provision of care

Cox, M. C., Nusca, S. M., Landro, F. D., Marsilli, G., Stella, G. C., Sigona, M., Ponzelli, F., Passerini, J., Gregorio, F. D., Santoboni, F., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1842396 · Cited by 19 · see citing works

Current Immunotherapy Approaches in Non-Hodgkin Lymphomas

Pytlík, R., Polgárová, K., Karolová, J., & Klener, P. (2020) · Vaccines · doi:10.3390/vaccines8040708 · Cited by 17 · see citing works

Mitigating time toxicity in lymphoma and multiple myeloma

Di, M., Su, C. T., Cowan, A. J., Gopal, A. K., & Banerjee, R. K. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2352086 · Cited by 17 · see citing works

Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy

Sircar, A., Chowdhury, S. M., Hart, A., Bell, W. R., Singh, S. V., Sehgal, L., & Epperla, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030904 · Cited by 17 · see citing works

Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non‐Hodgkin Lymphoma

Apostolidis, J. P., Sayyed, A., Darweesh, M., Kaloyannidis, P., & Hashmi, H. A. (2020) · Journal of Immunology Research · doi:10.1155/2020/9350272 · Cited by 17 · see citing works

Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti–CD20-based Biological Therapy

Sohani, A. R., Maurer, M. J., Giri, S., Pitcher, B. N., Chadburn, A., SAID, J. W., Bartlett, N. L., Czuczman, M. S., Martin, P., Rosenbaum, C. A., et al. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001609 · Cited by 17 · see citing works

Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma

Menard, C., Rossille, D., Dulong, J., Nguyen, T.-T., Papa, I., Latour, M., Bescher, N., Bézier, I., Chouteau, M., Fest, T., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003774 · Cited by 17 · see citing works

Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade

Apostolidis, J. P., Mokhtar, N., Omari, R., Darweesh, M., & Hashmi, H. A. (2019) · Hematological Oncology · doi:10.1002/hon.2711 · Cited by 17 · see citing works

B Cell Lymphomas of the GI Tract

Small, S. H., Slonim, L. B., Williams, C. J., & Karmali, R. (2021) · Current Gastroenterology Reports · doi:10.1007/s11894-021-00811-8 · Cited by 16 · see citing works

Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas

Leslie, L. A. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00909-1 · Cited by 16 · see citing works

Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study

Ollila, T. A., Butera, J. N., Egan, P., Reagan, J. L., Thomas, A. G., Yakirevich, I., MacKinnon, K., Margolis, J. M., McMahon, J. B., Rosati, V., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab079 · Cited by 16 · see citing works

Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study

Barraclough, A., Agrawal, S., Talaulikar, D., Chong, G., Yoo, E., Cheah, C. Y., Franco, N. F., Nguyen, B., Mutsando, H., Tahir, F., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284538 · Cited by 16 · see citing works

The simplified follicular lymphoma PRIMA‐prognostic index is useful in patients with first‐line chemo‐free rituximab‐based therapy

Kimby, E. K., Lockmer, S., Holte, H., Hagberg, H., Wahlin, B. E., Brown, P. D. N., & Østenstad, B. (2020) · British Journal of Haematology · doi:10.1111/bjh.16692 · Cited by 16 · see citing works

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma

Neelapu, S. S., Adkins, S., Ansell, S. M., Brody, J., Cairo, M. S., Friedberg, J. W., Kline, J. P., Levy, R., Porter, D. L., van Besien, K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001235 · Cited by 16 · see citing works

Early Relapse in First-Line Follicular Lymphoma: A Review of the Clinical Implications and Available Mitigation and Management Strategies

Rodgers, T. D., Casulo, C., Boissard, F., Launonen, A., Parreira, J. M., & Cartron, G. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00161-5 · Cited by 16 · see citing works

Ikaros Proteins in Tumor: Current Perspectives and New Developments

Xia, R., Cheng, Y., Han, X., Wei, Y., & Wei, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.788440 · Cited by 15 · see citing works

Actualización en el diagnóstico, pronóstico y tratamiento del linfoma folicular

Mozas, P., Sorigué, M., & López‐Guillermo, A. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2021.03.041 · Cited by 15 · see citing works

Lenalidomide: A Review in Previously Treated Follicular Lymphoma

Blair, H. A. (2020) · Drugs · doi:10.1007/s40265-020-01381-1 · Cited by 19 · see citing works

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance)

Martin, P., Jung, S., Pitcher, B. N., Bartlett, N. L., Blum, K. A., Shea, T., Hsi, E. D., Ruan, J., Smith, S. E., Leonard, J. P., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx496 · Cited by 83 · see citing works

Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance

Morschhauser, F., Nastoupil, L. J., Feugier, P., de Colella, J. S., Tilly, H., Palomba, M. L., Bachy, E., Fruchart, C., Libby, E. N., Casasnovas, O., et al. (2021) · Blood · doi:10.1182/blood-2021-148218 · Cited by 3 · see citing works

An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date

Yilmaz, U., Salihoglu, A., & Soysal, T. (2021) · DOAJ (DOAJ: Directory of Open Access Journals)

Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)

Leonard, J. P., Jung, S., Johnson, J. L., Pitcher, B. N., Bartlett, N. L., Blum, K. A., Czuczman, M. S., Giguere, J. K., & Cheson, B. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.9258 · Cited by 180 · see citing works